Cambridge Healthtech Institute’s 5th Annual 

Global Site Selection, Feasibility Assessment,
Operations and Site Management
 

Improving Timelines and Outcomes with Strategy, Relationships, Data and Execution
February 24-25, 2015 | Hyatt Regency Orlando | Orlando, FL 


Data-driven global site selection, an optimized feasibility assessment process, and effective site management are critical to improving clinical trial timelines and outcomes. Too often companies fail to learn from past mistakes and take the same approach to trial planning and execution. In order to overcome challenges in clinical trial planning, operations and site management leaders should learn from the best practices of their peers, utilize data and technology to support decision making, and improve communication and relationships between Sites, CROs, and Sponsors. Cambridge Healthtech Institute’s Fifth Annual “Global Site Selection, Feasibility Assessment, Operations and Site Management” conference will cover the topics one should consider when planning and implementing a trial.

 

Protocol Design, Feasibility and Country Selection Strategies 

Employing Trial Design and Protocol Development Strategies That Support Study Site Compliance: Minimize Downstream Operational Challenges with Good Up-Front Design 

Jorge Rodriguez-Larrain, M.D., Head, Global Site Management, Global Clinical Operations, Alcon   

Global Trial Placement Strategies; Linking Early Research with Phase III Execution 

John Oidtman, Vice President, Clinical Trial Support and Compliance & WW Clinical Operations, Pfizer 

Adaptive Designs in Early Development 

Nancy Widener, Executive Director, Central Clinical Operations, Bristol-Myers Squibb 

Protocol Design, Feasibility and Country Selection: Integrating Teams and Processes for Improved Trial Execution 

Stephen Yoo, M.D., Chief Medical Officer, ReGenX Biosciences

 

Feasibility from the Sponsor, Investigator and Site Perspectives 

Optimizing Site Selection to Initiate and Maintain a Positive Site Relationship 

Christine Pierre, President, The Society for Clinical Research Sites (SCRS)   

Investigator Registries: Collaborating to Benefit Both Investigators and Sponsors in Feasibility, Site Selection, and Start-Up 

Susie Campos, Associate Director, Clinical Trial Intelligence, Novartis                 

Co-Presentation: Study Feasibility, the Sites’ First Hurdle 

Deena Bernstein, Director, Clinical Research, Sheridan Clinical Research, Inc. 

Chris Hoyle, President, Elite Research Network  

 

Improving Operational Efficiencies in Site, CRO, and Sponsor Interactions 

Additional Presentation Sponsored by BBK 



 

PANEL: Two Heads Are Better Than One: The Necessary Shift of Sponsors and CROs from Adversaries to Partners

Moderator: April Lewis, Director, Global Client Management, Clinical Trial Optimization Solutions, IMS Health
Panelists: Pfizer, Shire, PPD

BRIDGING LUNCHEON PRESENTATION: Optimizing Protocol Planning, Feasibility, and Site Selection through an Integrated View of Clinical Trial Operations and Other Data Sources 

Elisa Cascade, President, Hosted Data Solutions, DrugDev.org 

 

 

2015 Summit for Clinical Ops Executives (SCOPE) Conference at a Glance Large 

SCOPE 2014 Wrap-Up
Held February 4-6, 2014, in Miami, Florida, the 5th Annual SCOPE Summit gathered more than 700 industry leaders, an attendance increase of 18% from 2013, for three stimulating days of in-depth discussions covering important issues in clinical trial planning and management. With 11 different conference tracks, a Clinical Informatics News Best Practices Awards and two plenary keynote sessions, SCOPE offered advances and innovative solutions in all aspects of clinical trial management and operations, including Data Integration, Feasibility, Site Selection and Management, Recruitment and Retention, Social Media and Mobile Tech, Project Management, Forecasting, Aggregate Spend Compliance, Post-Marketing Studies, and Sample Logistics. The impressive executive audience at SCOPE came together for invaluable networking opportunities with more than 70% of the attendees titled as Executives from leading Pharma (16%), CRO (32%), and Biotech companies (26%). Industry leaders and key decision makers representing 16 different countries and more than 350 unique organizations shared case studies, collaborated on best practices and provided unique perspectives on poignant issues that the field currently faces.

For questions or suggestions about the meeting, please contact:
Micah Lieberman
Executive Director, Conferences
Cambridge Healthtech Institute (CHI)
T: (+1) 541.482.4709
E: mlieberman@healthtech.com 

 For partnering and sponsorship information, please contact:
Ilana Quigley
Manager, Business Development
Cambridge Healthtech Institute (CHI)
T: (+1) 781.972.5457
E: iquigley@healthtech.com 

For media and association partnerships, please contact:
Rich Handy
Senior Director, Marketing
Cambridge Healthtech Institute (CHI)
T: (+1) 781.972.5456
E: rhandy@healthtech.com 

About Cambridge Healthtech Institute (CHI)
Founded in 1992, Cambridge Healthtech Institute (CHI) (www.chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Events, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Marketing Services, and Cambridge Healthtech Media Group.


 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


> Event-At-A-Glance
Event-At-A-Glance 

> Download 2014 Brochure
  2014 SCOPE Brochure Image 

> Premier Sponsors 

 BBK 

 ClinicalInk 

Drug Dev 

IMS Health 

 Mapi 

OptumInsight

QUINTILES
 

> View All Sponsors 

> View Media Partners 

> Attendee Profile